|
|
|||
|
||||
OverviewArtificial Intelligence in Urologic Malignancies describes current artificial intelligence technology, with an emphasis on prostate cancer applications. The book provides guidance on how artificial intelligence can improve therapeutics, how the power of artificial intelligence integrated with current standard therapy and research can enhance decision-making, and proposes future directions on how to integrate artificial intelligence within clinical applications. This is the perfect reference for scientists and researchers interested in the basic translational research opportunities such as drug discovery, pharmacogenetics, and experimental therapeutics, as well as clinicians interested in how AI applications are integrated with applications. Full Product DetailsAuthor: Himanshu Arora, PhD (Research Assistant Professor, Assistant Professor of Research of Urology/Oncology (prostate cancer), Sylvester Cancer Centre, University of Miami, USA)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Weight: 1.120kg ISBN: 9780443155048ISBN 10: 0443155046 Pages: 270 Publication Date: 27 November 2024 Audience: Professional and scholarly , College/higher education , Professional & Vocational , Postgraduate, Research & Scholarly Format: Paperback Publisher's Status: Active Availability: Manufactured on demand We will order this item for you from a manufactured on demand supplier. Table of ContentsReviewsAuthor InformationDr. Arora is Assistant Professor in Department of Urology at Sylvester Cancer Centre, University of Miami. He is the recipient of the Young Investigator Award from Regional Center for Biotechnology, UNESCO, for working on drug discovery in cancer. In 2016 he joined the University of Miami as a research scientist. He has several peer reviewed articles, patents, and grants. In 2019 he was promoted to a faculty position at the University of Miami. Currently, his lab is focusing on exploring therapeutic efficacy of Nitric oxide donors against different stages of Prostate cancer progression, using Nitric oxide donors in combination with currently available immune checkpoint inhibitors, and using machine learning tools to study the progression of prostate cancer and applying this knowledge in building up translational tools that could be used by researchers, clinicians and patients. Tab Content 6Author Website:Countries AvailableAll regions |
||||